Finger-Prick Glucose Ketone Index Test Proposed as Practical Tool to Monitor Mitochondrial and Metabolic Health
Key Insights
Researchers propose the glucose ketone index (search) (GKI), a simple finger-prick blood test measuring the ratio of glucose to β-hydroxybutyrate (search), as a practical biomarker for tracking metabolic health in non-communicable diseases.
The GKI could help clinicians monitor whether diet, fasting, or exercise interventions shift the body toward nutritional ketosis, a state linked to improved mitochondrial function and potentially lower disease risk.
Non-communicable diseases including cancer (search), cardiovascular disease (search), and type 2 diabetes (search) account for roughly three-quarters of deaths worldwide, with mitochondrial dysfunction emerging as a common underlying feature.
A research review published in Frontiers in Science proposes that a simple finger-prick blood test—the glucose ketone index (search) (GKI)—could offer clinicians a practical, quantitative tool for assessing metabolic status and monitoring mitochondrial health in patients with cancer (search) and other chronic non-communicable diseases (NCDs).
The GKI measures the ratio of blood glucose to β-hydroxybutyrate (search), the primary ketone body produced during nutritional ketosis. Originally developed as a point-of-care biomarker for assessing dietary adherence in cancer (search) therapy, the test is now being advanced as a broader metabolic monitoring strategy. Lead author Thomas Seyfried, PhD, from Boston College, explained that "the GKI, which computes the ratio of glucose to the ketone body beta-hydroxybutyrate in blood, is a more stable biomarker for predicting systemic metabolic homeostasis than is glucose measurement alone."
The growing burden of non-communicable diseases
NCDs—including cancer (search), cardiovascular diseases, type 2 diabetes (search), obesity (search), and neurodegenerative conditions—currently account for roughly three-quarters of deaths worldwide. Within the next few decades, these conditions could represent up to 75% of all disability-adjusted life-years, contributing to a substantial decline in life expectancy. The authors emphasize that these conditions "are not the result of genetic fate but are largely shaped by lifestyle factors," with poor nutrition and reduced physical activity remaining among the most significant and preventable risk factors.
Emerging evidence suggests that many of these chronic diseases share a common feature: mitochondrial dysfunction, defined as the inability to efficiently regulate ATP production in response to energy demand. When mitochondria do not function efficiently, cells may fail to meet their energy requirements, triggering oxidative stress, cellular damage, and systemic inflammation.
How the GKI works
The GKI requires only a finger-prick blood sample and provides a ratio reflecting the balance between circulating glucose and ketones. Lower GKI values indicate lower blood glucose and higher ketone availability—metabolic conditions associated with more efficient mitochondrial energy production. Conversely, higher GKI values reflect higher glucose and lower ketone availability, which may signal impaired mitochondrial performance.
Seyfried noted that findings from the recent KetoSAge trial support this framework, showing that "the presence of a safe, elevated level of ketone bodies in the blood (euketonaemia) was associated with improved insulin sensitivity, liver function, and reduced pro-inflammatory and growth-related biomarkers." He added that "higher GKI values indicated excessive insulin release, with worsening biomarker profiles despite seemingly normal glucose ranges."
Lead author Derek Lee, PhD, also from Boston College, stated: "We propose that the GKI can be used as a simple, quantitative blood biomarker for predicting mitochondrial health. We show that high GKI values are linked to increased disease risk while low GKI values are linked to reduced risk."
Clinical applications and monitoring potential
The authors argue that the GKI could help clinicians track whether interventions such as ketogenic diets, fasting, and regular physical activity are successfully shifting patients toward nutritional ketosis—a metabolic state that may reduce systemic inflammation, high blood glucose, high blood insulin, and reactive oxygen species production. The finger-prick format enables real-time tracking of metabolic responses, while future studies could test how these values relate to disease risk or progression.
"Mitochondrial dysfunction is linked to many chronic illnesses and cancers, with poor nutrition and reduced physical activity remaining among the most significant—and preventable—risk factors," Lee said. "When combined with evidence-based nutrition and exercise, the GKI could offer a framework for monitoring mitochondrial health across diverse patient groups and disease contexts."
Important caveats and limitations
The authors are careful to emphasize that ketogenic approaches should be considered as management strategies under specific circumstances rather than cures, and that any such approach should be undertaken under clinical supervision. The GKI is not intended to diagnose or cure disease.
Co-author Isabella Cooper, PhD, from the University of Westminster, UK, cautioned: "It is important to emphasize that achieving a low GKI is not a simple task for most people initially. A gradual start is essential with slow macronutrient changes, prioritizing electrolytes and hydration, and using the GKI to track your progress rather than relying on guesswork."
The path to clinical validation
The researchers call for larger, standardized clinical studies to determine whether GKI values can reliably predict disease risk, progression, or treatment response across different conditions. Disease-specific target ranges must still be validated, along with the effective time patients should spend within each range to achieve meaningful benefits.
The authors also urge future studies to standardize reporting of glucose, ketone, and GKI values—ideally weekly or daily—whenever ketosis is assessed clinically. They note that previous studies often report ketone or GKI values too infrequently, making cross-study comparison difficult. Additional biomarkers such as triglycerides, inflammatory markers, and insulin should be reported alongside the GKI to clarify whether a low GKI correlates with broader metabolic changes.
Cooper emphasized the urgency: "NCDs cause an unacceptably high, rapidly rising toll on global health across nearly all age groups. Introducing quantitative GKI testing could provide a clear, cohesive readout that goes beyond weight loss, and one that supports and tracks sustained behaviour change to help assess disease risk and treatment response."
She added: "To move this forward we urgently need larger, standardized clinical studies to test how well GKI values can predict health outcomes across different diseases, and to define disease-specific target ranges."